New engineered immune cell therapy tested for Tough-to-Treat blood cancers
NCT ID NCT07471789
Summary
This early-stage study is testing an experimental treatment called CART84 for adults with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) that has returned or not responded to other therapies. CART84 is a type of CAR T-cell therapy, where a patient's own immune cells are collected, modified in a lab to better target cancer cells, and then infused back into the patient. The main goals are to find a safe dose and see if the treatment shows early signs of helping to control these aggressive blood cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOBLASTIC LEUKAEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Hospital Clínic de Barcelona
RECRUITINGBarcelona, Barcelona, 08036, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitario y Politécnico La Fe
RECRUITINGValencia, Valencia, 46026, Spain
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.